Get to know our clinical trials
Clinical trial to evaluate raludotatug deruxtecan (R-DXd) in participants with rapidly progressing ovarian cancer, primary peritoneal cancer, or platinum-resistant fallopian tube cancer.
THE PRIMARY OBJECTIVE IS TO EVALUATE RALUDOTATUG DERUXTECAN, ALSO KNOWN AS R-DXD, AT EACH DOSE LEVEL.
Technical Summary
- A PHASE II/III, MULTICENTER, RANDOMIZED STUDY TO EVALUATE RALUDOTATUG DERUXTECAN (R-DXD), A CDH6-TARGETED ANTIBODY-DRUG CONJUGATE, IN PARTICIPANTS WITH RAPIDLY PROGRESSING OVARIAN CANCER, PRIMARY PERITONEAL CANCER, OR PLATINUM-RESISTANT FALLOPIAN TUBE CANCER.
- Code EudraCT: 2023-507914-28-00
- Protocol number: DS6000-109
- Promoter: Daiichi Sankyo Development Ltd
- Molecule/Drug: raludotatug deruxtecán (R-DXd)
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.